HomeEDIT • NASDAQ
Editas Medicine Inc
$3.45
Sep 27, 1:16:50 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$3.49
Day range
$3.45 - $3.63
Year range
$3.37 - $11.69
Market cap
284.54M USD
Avg Volume
1.85M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Jun 2024Y/Y change
Revenue
513.00K-82.23%
Operating expense
70.29M58.11%
Net income
-67.61M-67.80%
Net profit margin
-13.18K-844.33%
Earnings per share
-0.82-46.43%
EBITDA
-70.48M-65.63%
Effective tax rate
——
Total assets
Total liabilities
(USD)Jun 2024Y/Y change
Cash and short-term investments
279.11M-35.39%
Total assets
384.80M-29.00%
Total liabilities
152.79M7.57%
Total equity
232.01M—
Shares outstanding
82.48M—
Price to book
1.24—
Return on assets
-43.57%—
Return on capital
-59.99%—
Net change in cash
(USD)Jun 2024Y/Y change
Net income
-67.61M-67.80%
Cash from operations
-57.06M-47.41%
Cash from investing
51.95M300.20%
Cash from financing
322.00K-99.73%
Net change in cash
-4.79M-105.21%
Free cash flow
-37.87M-27.20%
About
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
Founded
Nov 2013
Employees
265
Search
Clear search
Close search
Google apps
Main menu